A total of 9 out of 12 patients demonstrated no tumor recurrence for up to 24 weeks; and those patients additionally demonstrated stronger anti-tumor responses as measured by lymphocyte proliferation and IFN-gamma. Here, IFNG is linked to neoplasm.